Niflugel (Niflumic Acid)

Niflumic Acid works by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production and thus reduces inflammation. Additionally, it blocks specific chloride channels in peripheral tissues, contributing to its analgesic effect when applied topically.

The dosage of Niflugel is determined by the prescribing healthcare professional based on the patient’s condition, severity, and treatment response. The prescriber will specify the amount to apply, frequency, and duration of therapy.

Safety of Niflugel in pregnancy or while breastfeeding has not been fully established. It should be used only if the potential benefit justifies the potential risk, and this decision must be made by a qualified healthcare provider.

To order Niflugel, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and import documentation.

Niflugel contains Niflumic Acid, a fenamate class NSAID, which differs chemically from more common topical NSAIDs such as diclofenac or ibuprofen. Fenamates may offer a distinct anti‑inflammatory profile and are sometimes preferred for patients who respond better to this subclass, though clinical choice depends on efficacy, tolerability, and physician judgment.

Store Niflugel at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Ensure the product is kept out of reach of children.

Niflugel is applied topically to clean, dry skin over the affected area. The prescribed amount is spread in a thin layer and gently massaged until absorbed. Hands should be washed after application, and the gel should not be covered with occlusive dressings unless directed by a clinician.

Serious risks include systemic gastrointestinal ulceration or bleeding, renal impairment, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and anaphylaxis. Patients should seek immediate medical attention if they experience severe skin reactions, unexplained bleeding, or signs of systemic toxicity.

Niflugel should not be used by individuals with known hypersensitivity to Niflumic Acid or other fenamate NSAIDs, on broken or infected skin, or in patients where systemic NSAID use is contraindicated, such as those with active peptic ulcer disease, severe renal impairment, or uncontrolled bleeding disorders.